148 related articles for article (PubMed ID: 3114304)
1. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL.
Golay A; Zech L; Shi MZ; Chiou YA; Reaven GM; Chen YD
J Clin Endocrinol Metab; 1987 Sep; 65(3):512-8. PubMed ID: 3114304
[TBL] [Abstract][Full Text] [Related]
2. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin is an important determinant of apoA-I catabolism.
Vergès B; Petit JM; Duvillard L; Dautin G; Florentin E; Galland F; Gambert P
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1364-9. PubMed ID: 16574896
[TBL] [Abstract][Full Text] [Related]
4. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
5. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein apolipoprotein A-I kinetics in obesity.
Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
Obes Res; 2005 Jun; 13(6):1008-16. PubMed ID: 15976143
[TBL] [Abstract][Full Text] [Related]
8. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.
Shepherd J; Packard CJ; Patsch JR; Gotto AM; Taunton OD
J Clin Invest; 1979 May; 63(5):858-67. PubMed ID: 221531
[TBL] [Abstract][Full Text] [Related]
9. Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.
Rader DJ; Schäfer J; Lohse P; Verges B; Kindt M; Zech LA; Steinmetz A; Brewer HB
J Clin Invest; 1993 Aug; 92(2):1009-17. PubMed ID: 8349786
[TBL] [Abstract][Full Text] [Related]
10. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.
Ooi EM; Watts GF; Chan DC; Nielsen LB; Plomgaard P; Dahlbäck B; Barrett PH
Atherosclerosis; 2010 May; 210(1):326-30. PubMed ID: 20031132
[TBL] [Abstract][Full Text] [Related]
11. Changes in lipoprotein kinetics associated with type 2 diabetes affect the distribution of lipopolysaccharides among lipoproteins.
Vergès B; Duvillard L; Lagrost L; Vachoux C; Garret C; Bouyer K; Courtney M; Pomié C; Burcelin R
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1245-53. PubMed ID: 24694333
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A-IV levels and phenotype distribution in NIDDM.
Vergès BL; Vaillant G; Goux A; Lagrost L; Brun JM; Gambert P
Diabetes Care; 1994 Aug; 17(8):810-7. PubMed ID: 7956623
[TBL] [Abstract][Full Text] [Related]
13. Effect of glipizide treatment on various aspects of glucose, insulin, and lipid metabolism in patients with noninsulin-dependent diabetes mellitus.
Reaven GM
Am J Med; 1983 Nov; 75(5B):8-14. PubMed ID: 6369970
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Petit JM; Brindisi MC; Pais de Barros JP; Lagrost L; Gambert P; Duvillard L
J Lipid Res; 2009 Jun; 50(6):1209-15. PubMed ID: 19168444
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
[TBL] [Abstract][Full Text] [Related]
16. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus.
Frénais R; Nazih H; Ouguerram K; Maugeais C; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M
J Clin Endocrinol Metab; 2001 May; 86(5):1962-7. PubMed ID: 11344192
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1151-8. PubMed ID: 12187390
[TBL] [Abstract][Full Text] [Related]
18. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution.
Brinton EA; Eisenberg S; Breslow JL
Arterioscler Thromb; 1994 May; 14(5):707-20. PubMed ID: 8172849
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile and its relation to fasting insulin level in non-insulin dependent diabetes mellitus (NIDDM).
Uddin F; Miah AK
Bangladesh Med Res Counc Bull; 1995 Aug; 21(2):64-72. PubMed ID: 8815864
[TBL] [Abstract][Full Text] [Related]
20. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Pietzsch J; Julius U; Nitzsche S; Hanefeld M
Diabetes; 1998 Dec; 47(12):1928-34. PubMed ID: 9836526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
